Quote from blondeamazonrn
the h&h goes up faster if its given sc? why not give the patient the choice? ask them if they will take it sc and have the doctor write either/or. never heard that it made a difference, but am all for it if it works.
hemodialysis — epo given subcutaneously three times a week will maintain the hematocrit at the same level and at a lower dose than intravenous epo. in almost all published studies, subcutaneous administration is associated with a 25 to 50 percent epo dose reduction [1-8
]. as an example, an unblinded 26 week study evaluated 208 chronic hemodialysis patients who were randomized to either subcutaneous or intravenous therapy; the target hematocrit was 30 to 33 percent [6
]. the average weekly dose of epo was 32 percent less for those randomly assigned to the subcutaneous regimen (94 versus 150 u/kg). the average hematocrit and hemoglobin levels were similar for both groups, and only one patient randomized to subcutaneous therapy withdrew because of pain. continued... http://www.uptodate.com/patients/con...gbbcyvkvnb9kli
subcutaneous versus intravenous administration of erythropoietin
improves its efficiency for the treatment of anaemia in haemodialysis patients http://ndt.oxfordjournals.org/cgi/co...ct/10/supp6/40 urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants. langer j
, obladen m
, dame c
klinik für neonatologie, campus virchow-klinikum, charité-universitätsmedizin, berlin, germany.
hematopoietic and non-hematopoietic effects of recombinant erythropoietin (epo) given to preterm infants are controversially discussed. because renal loss of epo was significantly higher after intravenous versus subcutaneous epoetin-beta administration, we suggest a reconsideration of whether subcutaneous recombinant epo is more efficient and safer because of lower peaks of circulating epo.
pmid: 18410782 [pubmed - indexed for medline]